Jakob J et al (2018) Regional chemotherapy by isolated limb perfusion prior to surgery compared with surgery and post-operative radiotherapy for primary, locally advanced extremity sarcoma: a comparison of matched cohorts. Clin Sarcoma Res 8:1–9

Article  Google Scholar 

Sevilla-Ortega L et al (2021) Role of isolated limb perfusion in the era of targeted therapies and immunotherapy in melanoma. A systematic review of the literature. Cancers (Basel) 13:5485

Bhangu A, Broom L, Nepogodiev D, Gourevitch D, Desai A (2013) Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma: A systematic review. Eur J Surg Oncol 39:311–319

Article  CAS  PubMed  Google Scholar 

Davies EJ, Reijers SJM, Van Akkooi ACJ, Van Houdt WJ, Hayes AJ (2022) Isolated limb perfusion for locally advanced melanoma in the immunotherapy era. Eur J Surg Oncol 48:1288–1292

Article  CAS  PubMed  Google Scholar 

Klopp CT, Alford TC, Bateman J, Berry GN, Winship T (1950) Fractionated intra-arterial cancer; chemotherapy with methyl bis amine hydrochloride; a preliminary report. Ann Surg 132:811–832

Article  CAS  PubMed  PubMed Central  Google Scholar 

Creech O Jr, Ryan RF, Krementz ET (1959) Treatment of melanoma by isolation-perfusion technique. J Am Med Assoc 169:339–343

Article  PubMed  Google Scholar 

Cavaliere R et al (1967) Selective heat sensitivity of cancer cells. Biochem Clin Stud Cancer 20:1351–1381

CAS  Google Scholar 

Grünhagen DJ, de Wilt JHW, ten Hagen TLM, Eggermont AMM (2006) Technology Insight: utility of TNF-α-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Clin Pract Oncol 3:94–103

Article  PubMed  Google Scholar 

Moreno-Ramirez D, Cruz-Merino L, Ferrandiz L, Villegas-Portero R, Nieto-Garcia A (2010) Isolated Limb Perfusion for Malignant Melanoma: Systematic Review on Effectiveness and Safety. Oncologist 15:416–427

Article  PubMed  PubMed Central  Google Scholar 

Vrouenraets BC, Nieweg OE, Kroon BBR (1996) Thirty-five years of isolated limb perfusion for melanoma: Indications and results. Br J Surg 83:1319–1328

Article  CAS  PubMed  Google Scholar 

Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol Off J Am Soc Clin Oncol 10:52–60

Article  CAS  Google Scholar 

Lejeune FJ (2002) Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. J Clin Invest 110:433–435

Article  CAS  PubMed  PubMed Central  Google Scholar 

Van Der Veen AH et al (2000) TNF-α augments intratumoural concentrations of doxorubicin in TNF-α-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 82:973–980

Article  PubMed  PubMed Central  Google Scholar 

Eggermont AMM et al (1996) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: The cumulative multicenter European experience. Ann Surg 224:756–765

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonvalot S et al (2009) Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient. Ann Surg Oncol 16:3350–3357

Article  PubMed  Google Scholar 

Hayes AJ, Neuhaus SJ, Clark MA, Thomas JM (2007) Isolated limb perfusion with melphalan and tumor necrosis factor α for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol 14:230–238

Article  PubMed  Google Scholar 

Bonvalot S et al (2005) Limb salvage with isolated perfusion for soft tissue sarcoma: Could less TNF-α be better? Ann Oncol 16:1061–1068

Article  CAS  PubMed  Google Scholar 

Podleska LE et al (2014) Drug dosage in isolated limb perfusion: Evaluation of a limb volume model for extremity volume calculation. World J Surg Oncol 12:1–9

Article  Google Scholar 

Deroose JP et al (2011) Long-term results of tumor necrosis factor α- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J Clin Oncol 29:4036–4044

Article  CAS  PubMed  Google Scholar 

Van Ginkel RJ et al (2007) Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: Three time periods at risk for amputation. Ann Surg Oncol 14:1499–1506

Article  PubMed  PubMed Central  Google Scholar 

Erdmann F et al (2013) International trends in the incidence of malignant melanoma 1953–2008-are recent generations at higher or lower risk? Int J Cancer 132:385–400

Article  CAS  PubMed  Google Scholar 

Gershenwald JE, Scolyer RA (2018) Melanoma staging: American joint committee on cancer (AJCC) 8th edition and beyond. Ann Surg Oncol 25:2105–2110

Article  PubMed  Google Scholar 

Wolchok JD et al (2022) Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol 40:127–137

Article  CAS  PubMed  Google Scholar 

Lebbé C et al (2019) Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: Results from the phase IIIb/IV CheckMate 511 trial. J Clin Oncol 37:867–875

Article  PubMed  PubMed Central  Google Scholar 

Ascierto PA et al (2013) Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 31:3205–3211

Article  CAS  PubMed  Google Scholar 

Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S (2018) Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2018

Hayes AJ, Clark MA, Harries M, Thomas JM (2004) Management of in-transit metastases from cutaneous malignant melanoma. Br J Surg 91:673–682

Article  CAS  PubMed  Google Scholar 

Read RL et al (2015) In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy. Ann Surg Oncol 22:475–481

Article  PubMed  Google Scholar 

Andtbacka RHI et al (2019) Final analyses of OPTiM: A randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer 7:1–11

Article  Google Scholar 

Nan Tie E, Henderson MA, Gyorki DE (2019) Management of in-transit melanoma metastases: a review. ANZ J Surg 89:647–652

Article  PubMed  Google Scholar 

Patel A, Carr MJ, Sun J, Zager JS (2022) In-transit metastatic cutaneous melanoma: current management and future directions. Clin Exp Metastasis 39:201–211

Article  PubMed  Google Scholar 

Eggermont AMM et al (2016) Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med 375:1845–1855

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schachter J et al (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390:1853–1862

Article  CAS  PubMed  Google Scholar 

Weber J et al (2017) Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 377:1824–1835

Article  CAS  PubMed  Google Scholar 

Long GV et al (2017) Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma. N Engl J Med 377:1813–1823

Article  CAS  PubMed  Google Scholar 

Deroose JP et al (2012) 20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters. Ann Surg Oncol 19:627–635

Article  PubMed  Google Scholar 

Koops HS et al (1998) Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World He. J Clin Oncol Off J Am Soc Clin Oncol 16:2906–2912

Article  CAS  Google Scholar 

Cornett WR et al (2006) Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group trial Z0020. J Clin Oncol 24:4196–4201

Article  CAS  PubMed  Google Scholar 

Lejeune FJ, Eggermont AMM (2007) Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs [7]. J Clin Oncol 25:1449–1450

Article  PubMed  Google Scholar 

Thompson JF, Kam PC, Waugh RC, Harman CR (1998) Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 14:238–247

Article  CAS  PubMed  Google Scholar